Tandem Diabetes sees FY25 revenue $1.065B to $1.085B, consensus $1.10B

FY26 gross margin is estimated to be approximately 56% to 57% of sales. Adjusted EBITDA margin is estimated to be approximately 5% to 6% of sales. “In 2026, our goal is to expand the worldwide market by delivering double-digit pump shipment growth. We are adopting a pay-as-you-go model in the U.S. that provides affordable access to customers, and progresses our business toward more predictable and profitable revenue that may not be evident in our 2026 sales expectations,” said Leigh Vosseller, executive vice president and chief financial officer. “We remain committed to improving margins and profitability during this transition that positions Tandem for accelerated sales growth in 2027 and beyond.”